

David L. Van Brunt, Ph.D.

**Senior Research Fellow, Senior Director and
Head, Division of Evidence and Analytics**

Health Economics Outcomes and Research

AbbVie Inc.

Dr. Van Brunt leads the Division of Evidence and Analytics, a team within Health Economics and Outcomes Research (HEOR) focused on the expansion of Real-World Evidence and Patient-Centered Outcomes.

Dr. Van Brunt's work in Health Outcomes has spanned the product Lifecycle across many therapeutic areas at AbbVie, Biogen Idec and Eli Lilly. He joined industry from the faculty of the College of Medicine at the University of TN Health Sciences Center in the Division of Biostatistics and Epidemiology.

Dr. Van Brunt's PhD is in Psychology, with concentrations in Behavioral Medicine and research methods. His prior clinical career was with the US Air Force, where he served as Chief of Psychology Services at the US Strategic Command Headquarters; it is in this role that he first turned his attention from individual to population health.



Christophe Segalini, PharmD, MBA

Head, Global Value & Access

Idorsia Pharmaceuticals Ltd


Christophe Segalini is the Head, Global Value & Access at Idorsia Pharmaceuticals Ltd. since September 2019.

He has over 25 years of commercial experience with several major companies in the biopharma industry and over multiple markets, with the last decade spent focusing on Market Access and Pricing.

In that time, Christophe has led efforts to understand payer perspectives and develop the market access strategies for products in early development, including the payer value proposition, pricing strategy and reimbursement support across multiple disease areas and markets.

He has addressed market access challenges from a variety of vantage points including Global and market-based roles, where he has built teams, processes, and a knowledge base to help companies execute market access strategies that anticipate and meet the needs of access decision makers.

Christophe holds a Pharm D from the University of Lille, France and an MBA from the Kellogg School of Management at Northwestern University, USA.



Gregory Daniel, Ph.D., M.P.H., M.S.

Head, US Healthcare Policy

Edwards Lifesciences, LLC

Gregory Daniel is Head of US Healthcare Policy for Edwards Lifesciences (NYSE:EW), the global leader in patient-focused innovations for structural heart, as well as critical care and surgical monitoring. He is responsible for developing, evolving and advancing the Edwards U.S. healthcare policy strategy, value-based healthcare initiatives, payment policy, healthcare delivery system reform, and other high priority policy initiatives.

Greg has 20 years of distinguished experience in healthcare delivery, research, and policy. As a recognized health policy leader, Greg spent almost a decade leading pharmaceutical and medical device policy in the areas of value-based healthcare and payment, real-world evidence development, and FDA regulatory science both at The Brookings Institution and the Duke-Margolis Center for Health Policy. Immediately prior to joining Edwards, Greg was the Deputy Director at the Duke-Margolis Center for Health Policy and Clinical Professor at Duke's Fuqua School of Business where he directed the Washington, DC office and led the Center's biomedical innovation policy portfolio. Prior to that he was a Fellow and Managing Director at the Brookings Institution and Vice President, Government and Academic Research, at HealthCore Inc., an Anthem Company.

Greg holds a Ph.D. in Pharmaceutical Economics, Policy, and Outcomes from the University of Arizona, and an M.P.H. in Biostatistics, M.S. in Pharmaceutical Administration and a B.S. in Pharmacy, all from The Ohio State University.



Jeremy A. Rassen, Sc.D.

**President and
Chief Science Officer**

Aetion, Inc.

Jeremy A. Rassen, MS, ScD is a pharmacoepidemiologist with 25 years of academic and industry experience.

Prior to founding Aetion, Dr. Rassen was Assistant Professor of Medicine at Harvard Medical School, where he focused on methods to improve the quality and validity of real-world data studies. He also worked in Silicon Valley in a variety of technology companies.

Dr. Rassen received his bachelor's degree in Computer Science from Harvard College and his master's and doctorate degrees in Epidemiology from the Harvard T.H. Chan School of Public Health.



Panelists



Gregory Daniel

Head, US Healthcare Policy
Edwards Lifesciences, LLC



Jeremy Rassen

President and Chief
Science Officer
Aetion, Inc.



Christophe Segalini

Head, Global Value & Access
Idorsia Pharmaceuticals Ltd



David Van Brunt

Senior Research Fellow,
Senior Director and Head,
Division of Evidence and
Analytics
Health Economics
Outcomes and Research
AbbVie Inc.